Fc gamma RIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients

• Type: Article in International Scientific Journal
• Date: 2008

Authors

Marcia Paiva (Author) Other; Herlander Marques (Author) Other; Angelo Martins (Author) Other; Paula Ferreira (Author) Other; Raquel Catarino (Author) Other; Rui Medeiros (Author) ICBAS

Journal

Title: Cancer Genetics and Cytogenetics

Vol. 183

Pages: 35-40

ISSN: 0165-4608

Publisher: Elsevier B.V.

Indexing

ISI Web of Knowledge - 32 Citations

Scopus - 37 Citations

Scientific classification

FOS: Medical and Health sciences > Clinical medicine

Other information

Authenticus ID: P-003-ZJH

DOI: 10.1016/j.cancergencyto.2008.02.001

Abstract (EN): Rituximab is a chimeric monoclonal antibody that specifically targets the CD20 surface marker expressed in neoplastic B-lymphoid cells. Combined with chemotherapy or alone, in maintenance/consolidation, it is used for the treatment of non-Hodgkin lymphoma (NHL). The role of a polymorphism in a specific Fc gamma receptor gene, Fc gamma RIIa, in the clinical outcome of patients with NHL was investigated in this study. We characterized DNA samples from 64 non-Hodgkin lymphoma patients treated with rituximab using a polymerase chain reaction-restriction fragment length polymorphism method. The Fc gamma RIIa HH genotype was significantly correlated with complete response to rituximab compared to the R allele (P=0.028). In terms of overall or event-free survival, no difference was found according to Fc gamma RIIa alleles. We hypothesize that the HH genotype increases the affinity of the Fc gamma RIIa receptor, not only for naturally occurring IgG2, but also to ameliorate connection with chimeric IgG1 rituximab, contributing to a genetic individual profile of great interest in clinical onco-hematology.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 6